InMed Pharmaceuticals Inc. (INM) AI Dilution Summary

Cash was $2,194,413 at 2026-06-30 against estimated monthly burn of $720,293. The funding channels are an active at-the-market program with H.C. Wainwright & Co., LLC, authorised to $1,213,648, and a Yorkville equity line. The YA II PN, Ltd. (Yorkville) equity line is the main source of dilution.